喘可治对慢性阻塞性肺疾病患者外周血单个核细胞分泌白介素-17A的影响  

Effects of Chuankezhi injection on interleukin-17A patients with chronic obstructive pulmonary disease secretion of peripheral blood mononuclear cells in HONG

作　　者：洪春霖[1] 洪敏俐[1] 陈慧暖[1] 李德秀[1] 宋小玲[1] 陈文喜[1] 高凌云[1] 柯庚申[1] 

机构地区：[1]福建中医药大学附属漳州市中医院,363000

出　　处：《中华老年医学杂志》2013年第9期951-953,共3页Chinese Journal of Geriatrics

基　　金：基金项目：福建省卫生厅医学创新课题（2009CXB-42）;漳州市科技局课题（Z20111064）;福建省中医肺系病重点研究室建设项目

摘　　要：目的探讨喘可治注射液对慢性阻塞性肺疾病（COPD）稳定期患者外周血单个核细胞（PBMcs）分泌白介素-17A（IL-17A）的影响。方法分离稳定期COPD患者和健康对照的PBMCs，加入植物凝集素（PHA），并在PHA基础上加入不同浓度（2％、4％、6％）的喘可治，经培养48h后，用酶联免疫吸附（EusA）法测定培养物上清液中IL-17A浓度。结果经PHA诱导活化后，COPD组PBMCs培养物上清液IL-17A浓度明显升高，并高于健康对照组；COPD组活化后与活化前比较，[（153．89±45．07）ng／L比（10．21±2．27）ng／L；t=12．265，P〈0．0013，两组活化后比较[（153．89±45．07）ng／L比（110．23±53．99）ng／L；t=2．404，P=0．023]；加入喘可治后，COPD组PBMCs培养物上清液IL-17A浓度降低，并呈剂量依赖负相关（r=-0．599，P〈0．001）。结论喘可治可以抑制COPD稳定期患者PBMCs分泌IL17A。Objective To explore the effects of Chuankezhi （CKZ） injection on interleukin-17A （IL-17A） production of peripheral blood mononuclear cells （PBMCs） in patients with chronic obstructive pulmonary disease（COPD）. Methods PBMCs from patients with stable COPD and health controls were cultured in RPMI-1640 media with phytohemagglutinin （PHA） plus different doses of CKZ （2%, 4% and 6%）. The concentration of IL-17A in the supernatants was determined by ELISA after 48 hours of incubation. Results Compared with baseline, the level of IL-17A stimulated by PHA was increased significantly in COPD group （153. 89±45.07）ng/L vs. （10. 21± 2.27）ng/L, t=12. 265, P〈0. 001. The level of IL-17A stimulated by PHA was higher in COPD group than in health controls （153.89 ± 45.07） ng/L vs. （110.23 ± 53.99） ng/L, t = 2. 404, P= 0. 023. The level of IL-17A was significantly decreased in COPD group after CKZ intervention, which showed a negative correlation with CKZ dose （r=-0. 599,P〈0. 001）. Conclusions CKZ can inhibit IL-17A production of PBMCs in patients with stable COPD, which may be one of the mechanisms of CKZ in COPD treatment.

关 键 词：止咳平喘药 肺疾病 慢性阻塞性 单核细胞 白介素17A 

分 类 号：R563.9[医药卫生—呼吸系统]